CliffBio
small molecule

EYSUVIS

LOTEPREDNOL ETABONATE

Loss of exclusivityMay 2033latest FDA-listed patent expiry
CompanyAlcon →See this company's full patent-cliff portfolio

Drug detail

Brand nameEYSUVIS
Active ingredientLOTEPREDNOL ETABONATE
Strength0.25%
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalOctober 2020
Marketing statusRX

Listed patents

PatentExpiresType
11219596May 2033use U-2985
11596599May 2033use U-2985
10857096May 2033use U-2985
10945948May 2033use U-2985
10940108May 2033use U-2985
9532955May 2033use U-2491
9737491May 2033use U-2492
9056057May 2033product
9827191May 2033product
10058511May 2033product
10993908May 2033use U-3117
12115246May 2033product
11642317May 2033product
10688045May 2033product
10646436May 2033product
9393213May 2033product
11872318May 2033product

More from Alcon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EYSUVIS patent cliff — loss of exclusivity May 2033 | CliffBio